South Korea-based Samsung Biologics has completed the acquisition of GSK’s Human Genome Sciences manufacturing facility in Rockville, Maryland, marking the company’s first manufacturing site in the US.
This completion follows the company’s announcement in December 2025, when it laid out its intentions to acquire the facility.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The $353m purchase expands Samsung Biologics’ total drug substance production capacity to 845,000 litres with the addition of two cGMP plants at the Rockville location, which collectively offer 60,000 litres of capacity for both clinical and commercial biologics production.
The company will maintain the supply of products previously manufactured at the site for GSK under existing agreements, while also making the facility available for new contract manufacturing projects.
Samsung Biologics has stated its intention to further invest in the Rockville plant, with plans to expand capacity and introduce technology upgrades over time.
Company representatives indicated they will assess current capabilities and equipment to determine future development at the facility.
Maryland Governor Wes Moore attended a ribbon-cutting event at the Rockville site alongside Samsung Biologics executives and local officials.
The acquisition retains more than 500 jobs in Maryland and establishes a base for potential further investment by the company.
Samsung Biologics cited Maryland’s biopharmaceutical sector and proximity to federal research institutions as factors in choosing Rockville for its US expansion.
Samsung Biologics president and CEO John Rim said: “This represents a meaningful step in expanding our US manufacturing footprint.
“The addition of the Rockville site strengthens our ability to operate a geographically diversified manufacturing network, and we are thrilled to officially welcome more than 500 colleagues at the site to the Samsung Biologics family.”
Moore said: “During our international trade mission last year, we met with the Samsung Biologics team in Seoul to discuss the economic momentum in Maryland. Today’s ribbon cutting is the realisation of that meeting and our state’s momentum.”
State officials noted that other recent investments by international life sciences firms have contributed to employment growth in the region.
Maryland currently hosts nearly 5,000 life sciences businesses employing over 54,000 workers.
Samsung Biologics’ entry into the market is expected to support regional industry growth and provide expanded manufacturing options for pharmaceutical clients.
